.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
McKesson
UBS
US Army
Cerilliant
Julphar
McKinsey
Baxter
Dow
Merck

Generated: September 22, 2017

DrugPatentWatch Database Preview

Hoffmann La Roche Company Profile

« Back to Dashboard

What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?

HOFFMANN LA ROCHE has fourteen approved drugs.

There are fourteen US patents protecting HOFFMANN LA ROCHE drugs.

There are four hundred and eleven patent family members on HOFFMANN LA ROCHE drugs in fifty-two countries.

Summary for Applicant: Hoffmann La Roche

Patents:14
Tradenames:12
Ingredients:11
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-002Mar 24, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Hoffmann La Roche
FORTOVASE
saquinavir
CAPSULE;ORAL020828-001Nov 7, 1997DISCNYesNo► Subscribe► SubscribeY► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-002May 7, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
ACCUTANE
isotretinoin
CAPSULE;ORAL018662-003May 7, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-001May 16, 2003DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Hoffmann La Roche
ROCEPHIN
ceftriaxone sodium
INJECTABLE;INJECTION063239-002Aug 13, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
BONIVA
ibandronate sodium
TABLET;ORAL021455-002Mar 24, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Hoffmann La Roche
ZELBORAF
vemurafenib
TABLET;ORAL202429-001Aug 17, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
VALCYTE
valganciclovir hydrochloride
TABLET;ORAL021304-001Mar 29, 2001ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hoffmann La Roche

Paragraph IV activity for HOFFMANN LA ROCHE drugs

Drugname Dosage Strength Tradename Submissiondate
valganciclovir hydrochloride
For Oral Solution50 mg/mL
VALCYTE
3/21/2011
capecitabine
Tablets150 mg and 500 mg
XELODA
11/10/2008
ibandronate sodium
Injection1 mg/mL, 3 mL Vial
BONIVA
8/31/2007
ibandronate sodium
Tablets2.5 mg and 150 mg
BONIVA
5/16/2007
valganciclovir hydrochloride
Tablets450 mg
VALCYTE
12/27/2005

Premature patent expirations for HOFFMANN LA ROCHE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Hoffmann La Roche

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,663,517Compositions and uses thereof► Subscribe
8,889,109Pharmaceutical dosage forms comprising valganciclovir hydrochloride► Subscribe
6,627,221 Pharmaceutical composition containing diphosphonic acid or salt thereof► Subscribe
8,415,469Compounds and methods for kinase modulation, and indications therefor► Subscribe
7,846,941Compounds modulating c-kit and c-fms activity and uses therefor► Subscribe
8,530,661Process for the manufacture of pharmaceutically active compounds► Subscribe
8,329,724Process for the manufacture of pharmaceutically active compounds► Subscribe
8,067,434Compounds and methods for development of Ret modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hoffmann La Roche Drugs

Country Document Number Estimated Expiration
TaiwanI404719► Subscribe
Argentina054350► Subscribe
Hungary225035► Subscribe
Israel187344► Subscribe
TaiwanI347188► Subscribe
San MarinoT201500302► Subscribe
Peru04402004► Subscribe
Canada2671470► Subscribe
Argentina069942► Subscribe
Australia2007332640► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hoffmann La Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2Finland► Subscribe
00045Netherlands► SubscribePRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
90026-2Sweden► SubscribePRODUCT NAME: VEMURAFENIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/12/751/001 20120217
2012000043Germany► SubscribePRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
0120016 00059Estonia► SubscribePRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012
00534Netherlands► SubscribePRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
035Luxembourg► Subscribe92035, EXPIRES: 20270217
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
01C/021Belgium► SubscribePRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Boehringer Ingelheim
Cerilliant
Johnson and Johnson
Novartis
Citi
McKinsey
McKesson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot